76.8 F
New York
Saturday, July 2, 2022

lexicon [NASDAQ: LXRX] Signs A Collaboration Agreement With AC Bioscience

Must read

Lexicon Pharmaceutical [NASDAQ: LXRX] reports that the pharmaceutical company has signed a partnership with AC biosciences. It will empower the utilization of clinical information by AC biosciences for LX2931 without permitting any license under any of Lexicon’s patent rights for the compound. The LX2931 molecule is actively not in development at the company. Moreover, It is a small molecule that inhibits S1P lyse.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.


“Following our shift around the rapid improvement and development of the LX9211 program we keep on assessing our pipeline. After the assessment we decide the best method to propel our expansive library of compounds and targets.” said Praveen VP of R&D. Furthermore,  “We are glad to team up with AC Bioscience. To enhance their attempts around S1P and anticipate learning additional info about this fascinating pathway.”

Under contract terms, the lexicon will receive an upfront payment. Moreover, it is entitled to receive installments payments adding up to $5.3 Million

More articles

Latest article



Download Free eBook For

The 5 Best Growth Stocks 2022

100% free. stop anytime no spam